RT Journal Article
SR Electronic
T1 Elevated polyreactive immunoglobulin G in immune mediated liver injuries with the need for immunosuppressive therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.04.24306873
DO 10.1101/2024.05.04.24306873
A1 Kirchner, Theresa
A1 Dalekos, George N.
A1 Zachou, Kalliopi
A1 Robles-Díaz, Mercedes
A1 Andrade, Raúl J.
A1 Sebode, Marcial
A1 Lohse, Ansgar
A1 Janik, Maciej K.
A1 Milkiewicz, Piotr
A1 Kolev, Mirjam
A1 Semmo, Nasser
A1 Bruns, Tony
A1 Gevers, Tom Jg
A1 Beretta-Piccoli, Benedetta Terziroli
A1 Wedemeyer, Heiner
A1 Jaeckel, Elmar
A1 Taubert, Richard
A1 Engel, Bastian
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/05/06/2024.05.04.24306873.abstract
AB Background and aim The distinction of drug-induced liver injury (DILI), drug-induced autoimmune-like hepatitis (DI-ALH) and autoimmune hepatitis (AIH) can be challenging due to overlapping clinical characteristics. Recently, polyreactive immunoglobulin G (pIgG) was identified as a novel biomarker with a higher accuracy for the diagnose of AIH than conventional autoantibodies. This retrospective multicenter study aimed to evaluate the diagnostic accuracy of pIgG to distinguish between AIH, DI-ALH and DILI and thus identify patients in need of immunosuppression.Methods Samples from 116 patients (AIH=81, DI-ALH=12, DILI=23) were recruited and compared to a control group (non-AIH-non-DILI-LD= 596) from existing biorepositories.Results No patient in the DILI-group but 98% in the AIH-and 92% in the DI-ALH-group received immunosuppressive treatment. pIgG levels were significantly higher in the AIH-group (1.9 normalized arbitrary units (nAU) compared to DILI (1.1 nAU, p<0.001) and non-AIH-non-DILI-LD (1.0 nAU, p<0.001). Median pIgG concentrations of the DI-ALH-group (1.7 nAU) were between AIH (p=.634) and DILI (p=.052). Patients that needed immunosuppressive therapy for remission induction had significantly higher pIgG concentrations compared to those with spontaneous recovery of liver injury (1.8 nAU vs. 1.1 nAU, p<.001). The overall accuracy of pIgG >1.27nAU to distinguish AIH from DILI (74%) and liver injuries with and without the need for immunosuppression (74%) was similar to that of ANA (71/74%) and SMA (74/70%) at cut-offs of ≥1/40.Conclusion Polyreactive IgG can be used to predict AIH in comparison to DILI and indicate the need for immunosuppressive therapy in the work-up of immune mediated or drug-induced liver injuries.Competing Interest StatementRichard Taubert and Elmar Jaeckel are inventors of the patent application for the use of anti-HIP1R/BSA for the diagnosis of AIH (granted patent: EP3701264 B1; running patent application: 16/754,006). EUROIMMUN Medizinische Labordiagnostika AG and Inova Diagnostics Inc. provided ELISAs free of charge for other projects of Richard Taubert and Bastian Engel. Ye H Oo thanks the Sir Jules Thorn Charitable Trust and Whitney Wood Fellowship. All other authors have nothing to disclose with regard to this paper.Funding StatementBastian Engel was supported by the PRACTIS Clinician Scientist Programme of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all patients at respective centers. Use of material and data from all patients in this multicenter study was approved by the respective local ethical committees. The study was approved by the local Ethics Committee (Number 5582 with last Update from 2018, Hannover Medical School Ethics Committee, Hannover Medical School, Hannover, Germany). The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAIHAutoimmune hepatitisAMAanti-mitochondrial antibodyANAantinuclear antibodyDI-ALHDrug-induced autoimmune-like hepatitisDILIDrug-induced liver injuryLKMLiver kidney microsomal antibodiesNon-AIH-non-DILI-LDnon-autoimmune hepatitis non-drug-induced liver injury - liver diseasepIgGpolyreactive immunoglobulin GSMAsmooth-muscle antigenSLAsoluble liver antigens